Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
42 Results for "
ST2
" in MedChemExpress (MCE) Product Catalog:
Products (42)
42 Results for "ST2" in MCE Product Catalog:
3
Target:
Research Areas:
1
1 Cited Publications
Cat. No.: HY-P70615
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL1RL1; ST2V; Interleukin 1 Receptor Like 1; Homolog Of Mouse Growth STimulation-Expressed; DER4; Suppressor Of Tumorigenicity 2; ST2; Interleukin 1 Receptor-Like 1 Isoform 2; T1; Interleukin 1 Receptor-Like 1 Isoform 1; Interleukin-1 Receptor-Like 1; Int
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P76666
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SULT2B1; Sulfotransferase 2B1; Sulfotransferase Family 2B Member 1; ST2B1; HSST2; Sulfotransferase Family Cytosolic 2B Member 1; Sulfotransferase Family, Cytosolic, 2B, Member 1; HydroxySTeroid Sulfotransferase SULT2B1a; HydroxySTeroid Sulfotransferase 2
Species:
Human
Source:
E. coli
Cat. No.: HY-168532
CAS No.: 3099811-61-4
Target:
Research Areas:
ST2-IN-1 is a ST2 inhibitor. ST2-IN-1 blocks the binding interaction between ST2 and IL-33, thereby attenuating the downstream ST2/IL-33 signaling pathway. ST2-IN-1 reduces IL-1β release from mast cells and alleviates ST2 upregulation in cells. ST2-IN-1 can be used for research on inflammatory and immune-related diseases .
Cat. No.: HY-P99729
CAS No.: 2222865-46-3
Synonyms: GSK 3772847; CNTO-7160
Target:
Research Areas:
Cat. No.: HY-155193
Purity: 99.77%
Target:
Research Areas:
XY-52 (Compound 32) is a Stimulation-2 (ST2) inhibitor, with an IC50 value of 5.68 μM in AlphaLISA assay, and 4.59 μM in HEK-Blue assay. XY-52 increases proinflammatory T-cell proliferation. XY-52 reduces the plasma sST2 and IFNγ biomarkers in the graft versus host disease (GVHD) mice model .
Cat. No.: HY-P991633
Target:
Research Areas:
Cat. No.: HY-RS06725
Target:
Research Areas:
IL1RL1 Human Pre-designed siRNA Set A contains three designed siRNAs for IL1RL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS29497
Target:
Research Areas:
GAL3ST2 Human Pre-designed siRNA Set A contains three designed siRNAs for GAL3ST2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Components
GAL3ST2 siRNA-1: 5 nmol (HPLC)
GAL3ST2 siRNA-2: 5 nmol (HPLC)
GAL3ST2 siRNA-3: 5 nmol (HPLC)
siRNA Negative Control: 5 nmol (HPLC)
FAM-labeled siRNA Negative Control: 5 nmol (HPLC)
GAPDH siRNA Positive Control: 5 nmol (HPLC)
Components
GAL3ST2 siRNA-1: 5 nmol (HPLC)
GAL3ST2 siRNA-2: 5 nmol (HPLC)
GAL3ST2 siRNA-3: 5 nmol (HPLC)
siRNA Negative Control: 5 nmol (HPLC)
FAM-labeled siRNA Negative Control: 5 nmol (HPLC)
GAPDH siRNA Positive Control: 5 nmol (HPLC)
Cat. No.: HY-W060417
CAS No.: 1019158-02-1
Target:
Research Areas:
iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC50 value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4 + and CD8 + T cells, increases regulatory T cell populations, reduces IFN-γ +CD4 + T cell populations, increases Foxp3 +CD4 + regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease [2].
Cat. No.: HY-174607
Target:
Research Areas:
Human IL33 mRNA encodes the human interleukin 33 (IL33) protein, a cytokine that binds to the IL1RL1/ST2 receptor. IL33 is involved in the maturation of Th2 cells and the activation of mast cells, basophils, eosinophils and natural killer cells.
Cat. No.: HY-P11298
CAS No.: 2120397-85-3
Research Areas:
Cat. No.: HY-RS06378
Target:
Research Areas:
HS3ST2 Human Pre-designed siRNA Set A contains three designed siRNAs for HS3ST2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS06383
Target:
Research Areas:
HS6ST2 Human Pre-designed siRNA Set A contains three designed siRNAs for HS6ST2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P705134
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IL1RL1; ST2V; Interleukin 1 Receptor Like 1; Homolog Of Mouse Growth STimulation-Expressed; DER4; Suppressor Of Tumorigenicity 2; ST2; Interleukin 1 Receptor-Like 1 Isoform 2; T1; Interleukin 1 Receptor-Like 1 Isoform 1; Interleukin-1 Receptor-Like 1; Interleukin 1 Receptor-Related Protein; FIT-1; Growth STimulation-Expressed; IL33R; Protein ST2; ST2L
Species:
Human
Source:
HEK293
Cat. No.: HY-RS12584
Target:
Research Areas:
SDCBP2 Human Pre-designed siRNA Set A contains three designed siRNAs for SDCBP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P992440
Target:
Research Areas:
Cat. No.: HY-P71343
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SULT2A1; ST2; Prev. STD; DehydroepiandroSTerone Sulfotransferase; DHEA-ST; Bile-Salt Sulfotranasferase 2A1; Sulfotransferase Family, Cytosolic, 2A, DehydroepiandroSTerone (DHEA)-Preferring, Member 1; HydroxySTeroid Sulfotransferase; Sulfotransferase 2A1;
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
